Figure 1: Pathogen stimulation history modulates frequency of FcγRIIB-expressing cells and is correlated with prolonged graft survival.

OVA-specific Thy1.1⁺ CD8⁺ T cells (OT-I) were harvested from the spleen and adoptively transferred into WT B6 hosts that were then either infected with Listeria, Herpes, or Polyoma engineered to express OVA. Mice were bled on days 8 and 28. On day 30, mice were grafted with an OVA-expressing skin graft and treated with 250ug CTLA-4Ig, anti-CD154 (MR-1), and anti-VLA-4 on days 0, 2, 4 and 6 and graft survival was monitored. A) Schematic of experimental design. B) Graft survival, data from ref 13 Figure 3B–D, animals treated with CoB + anti- VLA4. Pooled data from two independent experiments, n=7 per group. A log-rank (Mantel-Cox) test was performed to compare groups **p<0.01, ****p<0.0001. C-D) Representative flow plots and summary data of the frequency of FcγRIIB-expressing cells on day 8 post infection in the peripheral blood. Pooled data from 2 independent experiments, n=7–8 mice per group. One-way ANOVA was performed with multiple comparisons, ****p<0.0001. E-F) Representative flow plots and summary data of the expression of FcγRIIB on day 28 post infection in the peripheral blood. Pooled data from 2 independent experiments, n=7–8 mice per group. One-way ANOVA was performed with multiple comparisons ****p<0.0001. G) Summary data of D and F comparing day 8 and 28 frequencies of FcγRIIB. Two-way ANOVA was performed with multiple comparisons, ****p<0.0001. H) Linear regression of the frequency of FcγRIIB-expressing OT-I T cells on day 8 and 28 post infection and the median survival time.